Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors

Core Insights - Omega Therapeutics is a clinical-stage biotechnology company focused on developing programmable epigenomic mRNA medicines to treat a wide range of diseases, utilizing a novel approach that modulates gene expression without altering nucleic acid sequences [1][3][4] - The company has appointed Richard N. Kender to its Board of Directors, bringing extensive experience in corporate finance and business development from his 35-year career at Merck & Co., which will support Omega's business objectives [3][4][7] - Omega's pipeline includes therapeutic candidates derived from its OMEGA platform, targeting areas such as oncology, regenerative medicine, and multigenic diseases, including inflammatory and cardiometabolic conditions [1][3] Company Overview - Founded in 2017 by Flagship Pioneering, Omega Therapeutics is led by a seasoned leadership team with a strong track record in innovation and operational excellence [1] - The company aims to revolutionize genomic medicine through its unique epigenomic controllers, which have the potential to target historically difficult-to-treat diseases [1][6] Leadership and Expertise - Richard N. Kender's background includes significant roles in corporate development, M&A, and licensing at Merck, where he was involved in strategic transactions, including the acquisition of Schering Plough [4][6] - Kender's expertise is expected to provide strategic insights that will benefit Omega as it pursues its ambitious vision in the biotechnology sector [7]